Clinical Trial Update: Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated the safety, pharmacokinetics and pharmacodynamics of COR-1, a beta-1 receptor-targeting cyclopeptide, in heart failure patients, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• COR-1

Snippet

Sponsor: Corimmun GmbH | Conditions: Heart Failure | Phase 1 | Status: COMPLETED | Results posted: 2013-04-08